Description

Docetaxel (docetaxel) concentrate for infusions 20 mg/ml. 7 ml. (140 mg.) vial №1

Ingredients:

Docetaxel (docetaxel) concentrate for infusions 20 mg/ml, polysorbate 80, ethanol, citric acid, and water for injections.

Dosage:

The recommended dosage of Docetaxel concentrate for infusions is determined by the patient’s body surface area and the specific condition being treated. It is administered intravenously by a healthcare professional.

Indications:

Docetaxel concentrate for infusions is indicated for the treatment of various types of cancers including breast cancer, non-small cell lung cancer, prostate cancer, and gastric adenocarcinoma.

Contraindications:

Do not use Docetaxel concentrate for infusions if you have a history of severe hypersensitivity reactions to docetaxel or any of the other ingredients in the formulation.

Directions:

Administer Docetaxel concentrate for infusions under the supervision of a qualified healthcare provider experienced in the use of cytotoxic agents. Follow the specific instructions provided by your healthcare team.

Scientific Evidence:

Docetaxel has demonstrated efficacy in various clinical trials for the treatment of advanced cancers. Studies have shown its ability to inhibit microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells.

Additional Information:

It is important to monitor for potential side effects such as neutropenia, hypersensitivity reactions, and fluid retention during treatment with Docetaxel concentrate for infusions. Close medical supervision is necessary.

Docetaxel is a taxane chemotherapy medication that works by disrupting the microtubular network in cells, ultimately leading to cell death. It is commonly used in the treatment of various solid tumors and has shown efficacy both as a single agent and in combination with other chemotherapeutic drugs.

Clinical trials have demonstrated the effectiveness of Docetaxel in improving overall survival rates and progression-free survival in patients with advanced cancers. Its use has been well-established in the oncology field, with guidelines recommending its inclusion in treatment regimens for specific cancer types.